Published
{
"ticker": "A",
"cik": "0001090872",
"company": "Agilent Technologies Inc.",
"business_type": "industrial",
"schema_template": "standard (life-science and diagnostic instruments, consumables and services): revenue split into products and services, cost of revenue, gross profit, operating income, net income, EPS; cash, debt, assets, equity; operating cash flow, capital expenditures, free cash flow, dividends; revenue and operating income by reportable segment",
"reporting_currency": "USD",
"converted_to_usd": false,
"units": "actual US dollars (not millions); per-share amounts in dollars; weighted-average share counts in actual shares (the statements print them rounded to the nearest million); shares outstanding in actual shares",
"units_notes_seen": {
"FY2025 10-K consolidated statements of operations": "(in millions, except per share data)",
"FY2025 10-K consolidated balance sheets": "(in millions, except par value and share data)",
"FY2025 10-K consolidated statements of cash flows": "(in millions)",
"FY2025 10-K consolidated statements of equity": "(in millions, except number of shares in thousands)",
"Q3 FY2026 10-Q condensed consolidated statements of operations": "(in millions, except per share data)",
"Q3 FY2026 10-Q condensed consolidated balance sheets": "(in millions, except par value and share data)",
"Q3 FY2026 10-Q condensed consolidated statements of cash flows": "(in millions)",
"Q3 FY2026 10-Q condensed consolidated statements of equity": "(in millions, except number of shares in thousands and per share data)",
"Q3 FY2026 10-Q Note 18 segment information tables": "(in millions)",
"FY2025 10-K Note 22 segment information table": "(in millions)"
},
"adjustments": {
"splits_applied": [],
"splits_note": "No stock split falls within or between the periods presented, so no per-share restatement was applied.",
"adr_ratio": null,
"fx": "None. Agilent reports in US dollars."
},
"annual": [
{
"fiscal_year": 2025,
"label": "FY2025",
"period_start": "2024-11-01",
"period_end": "2025-10-31",
"period_type": "fiscal year",
"source_accession": "0001090872-25-000087",
"income_statement": {
"product_revenue": 4944000000,
"services_and_other_revenue": 2004000000,
"total_net_revenue": 6948000000,
"cost_of_products": 2237000000,
"cost_of_services_and_other": 1068000000,
"total_cost_of_revenue": 3305000000,
"research_and_development": 455000000,
"selling_general_and_administrative": 1709000000,
"total_costs_and_expenses": 5469000000,
"operating_income": 1479000000,
"interest_income": 62000000,
"interest_expense": -112000000,
"other_income_expense_net": 6000000,
"income_before_taxes": 1435000000,
"provision_for_income_taxes": 132000000,
"net_income": 1303000000,
"basic_eps": 4.59,
"diluted_eps": 4.57,
"basic_shares": 284000000,
"diluted_shares": 285000000,
"gross_profit": 3643000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 1789000000,
"accounts_receivable_net": 1487000000,
"inventory": 1025000000,
"other_current_assets": 293000000,
"total_current_assets": 4594000000,
"property_plant_and_equipment_net": 2023000000,
"goodwill": 4473000000,
"other_intangible_assets_net": 445000000,
"long_term_investments": 133000000,
"other_assets": 1059000000,
"total_assets": 12727000000,
"accounts_payable": 570000000,
"employee_compensation_and_benefits": 443000000,
"deferred_revenue": 624000000,
"short_term_debt": 304000000,
"other_accrued_liabilities": 406000000,
"total_current_liabilities": 2347000000,
"long_term_debt": 3050000000,
"retirement_and_post_retirement_benefits": 126000000,
"other_long_term_liabilities": 463000000,
"total_liabilities": 5986000000,
"total_stockholders_equity": 6741000000,
"total_debt": 3354000000,
"shares_outstanding": 283054377
},
"cash_flow": {
"depreciation_and_amortization": 288000000,
"share_based_compensation": 128000000,
"operating_cash_flow": 1559000000,
"capital_expenditures": -407000000,
"acquisitions_net_of_cash_acquired": 4000000,
"investing_cash_flow": -394000000,
"repurchase_of_common_stock": -425000000,
"dividends_paid": -282000000,
"proceeds_from_issuance_of_long_term_debt": 4000000,
"repayment_of_long_term_debt": -3000000,
"financing_cash_flow": -715000000,
"free_cash_flow": 1152000000
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": 2726000000,
"income_from_operations": 536000000
},
"agilent_crosslab": {
"net_revenue": 2908000000,
"income_from_operations": 946000000
},
"applied_markets": {
"net_revenue": 1314000000,
"income_from_operations": 301000000
},
"total_reportable_segment_income_from_operations": 1783000000
},
"per_share": {
"dividends_declared_per_share": 0.992
}
},
{
"fiscal_year": 2024,
"label": "FY2024",
"period_start": "2023-11-01",
"period_end": "2024-10-31",
"period_type": "fiscal year",
"source_accession": "0001090872-25-000087",
"income_statement": {
"product_revenue": 4672000000,
"services_and_other_revenue": 1838000000,
"total_net_revenue": 6510000000,
"cost_of_products": 2024000000,
"cost_of_services_and_other": 951000000,
"total_cost_of_revenue": 2975000000,
"research_and_development": 479000000,
"selling_general_and_administrative": 1568000000,
"total_costs_and_expenses": 5022000000,
"operating_income": 1488000000,
"interest_income": 80000000,
"interest_expense": -96000000,
"other_income_expense_net": 49000000,
"income_before_taxes": 1521000000,
"provision_for_income_taxes": 232000000,
"net_income": 1289000000,
"basic_eps": 4.44,
"diluted_eps": 4.43,
"basic_shares": 290000000,
"diluted_shares": 291000000,
"gross_profit": 3535000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 1329000000,
"accounts_receivable_net": 1324000000,
"inventory": 972000000,
"other_current_assets": 334000000,
"total_current_assets": 3959000000,
"property_plant_and_equipment_net": 1778000000,
"goodwill": 4477000000,
"other_intangible_assets_net": 547000000,
"long_term_investments": 175000000,
"other_assets": 910000000,
"total_assets": 11846000000,
"accounts_payable": 540000000,
"employee_compensation_and_benefits": 368000000,
"deferred_revenue": 544000000,
"short_term_debt": 45000000,
"other_accrued_liabilities": 398000000,
"total_current_liabilities": 1895000000,
"long_term_debt": 3345000000,
"retirement_and_post_retirement_benefits": 130000000,
"other_long_term_liabilities": 578000000,
"total_liabilities": 5948000000,
"total_stockholders_equity": 5898000000,
"total_debt": 3390000000,
"shares_outstanding": 285193011
},
"cash_flow": {
"depreciation_and_amortization": 257000000,
"share_based_compensation": 129000000,
"operating_cash_flow": 1751000000,
"capital_expenditures": -378000000,
"acquisitions_net_of_cash_acquired": -862000000,
"investing_cash_flow": -1258000000,
"repurchase_of_common_stock": -1150000000,
"dividends_paid": -274000000,
"proceeds_from_issuance_of_long_term_debt": 1197000000,
"repayment_of_long_term_debt": -600000000,
"financing_cash_flow": -752000000,
"free_cash_flow": 1373000000
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": 2466000000,
"income_from_operations": 484000000
},
"agilent_crosslab": {
"net_revenue": 2747000000,
"income_from_operations": 925000000
},
"applied_markets": {
"net_revenue": 1297000000,
"income_from_operations": 312000000
},
"total_reportable_segment_income_from_operations": 1721000000
},
"per_share": {
"dividends_declared_per_share": 0.944
}
},
{
"fiscal_year": 2023,
"label": "FY2023",
"period_start": "2022-11-01",
"period_end": "2023-10-31",
"period_type": "fiscal year",
"source_accession": "0001090872-25-000087",
"income_statement": {
"product_revenue": 5051000000,
"services_and_other_revenue": 1782000000,
"total_net_revenue": 6833000000,
"cost_of_products": 2428000000,
"cost_of_services_and_other": 940000000,
"total_cost_of_revenue": 3368000000,
"research_and_development": 481000000,
"selling_general_and_administrative": 1634000000,
"total_costs_and_expenses": 5483000000,
"operating_income": 1350000000,
"interest_income": 51000000,
"interest_expense": -95000000,
"other_income_expense_net": 33000000,
"income_before_taxes": 1339000000,
"provision_for_income_taxes": 99000000,
"net_income": 1240000000,
"basic_eps": 4.22,
"diluted_eps": 4.19,
"basic_shares": 294000000,
"diluted_shares": 296000000,
"gross_profit": 3465000000
},
"cash_flow": {
"depreciation_and_amortization": 271000000,
"share_based_compensation": 111000000,
"operating_cash_flow": 1772000000,
"capital_expenditures": -298000000,
"acquisitions_net_of_cash_acquired": -51000000,
"investing_cash_flow": -310000000,
"repurchase_of_common_stock": -575000000,
"dividends_paid": -265000000,
"proceeds_from_issuance_of_long_term_debt": 0,
"repayment_of_long_term_debt": 0,
"financing_cash_flow": -930000000,
"free_cash_flow": 1474000000
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": 2780000000,
"income_from_operations": 673000000
},
"agilent_crosslab": {
"net_revenue": 2656000000,
"income_from_operations": 839000000
},
"applied_markets": {
"net_revenue": 1397000000,
"income_from_operations": 363000000
},
"total_reportable_segment_income_from_operations": 1875000000
},
"per_share": {
"dividends_declared_per_share": 0.9
}
}
],
"quarterly": [
{
"fiscal_year": 2026,
"fiscal_quarter": 3,
"label": "Q3 FY2026",
"period_start": "2026-05-01",
"period_end": "2026-07-31",
"period_type": "three months",
"source_accession": "0001090872-26-000064",
"income_statement": {
"product_revenue": 1333000000,
"services_and_other_revenue": 545000000,
"total_net_revenue": 1878000000,
"cost_of_products": 559000000,
"cost_of_services_and_other": 277000000,
"total_cost_of_revenue": 836000000,
"research_and_development": 123000000,
"selling_general_and_administrative": 475000000,
"total_costs_and_expenses": 1434000000,
"operating_income": 444000000,
"interest_income": 15000000,
"interest_expense": -29000000,
"other_income_expense_net": 14000000,
"income_before_taxes": 444000000,
"provision_for_income_taxes": 82000000,
"net_income": 362000000,
"basic_eps": 1.28,
"diluted_eps": 1.28,
"basic_shares": 282000000,
"diluted_shares": 283000000,
"gross_profit": 1042000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 1758000000,
"accounts_receivable_net": 1478000000,
"inventory": 1117000000,
"other_current_assets": 340000000,
"total_current_assets": 4693000000,
"property_plant_and_equipment_net": 2134000000,
"goodwill": 5030000000,
"other_intangible_assets_net": 906000000,
"long_term_investments": 130000000,
"other_assets": 1074000000,
"total_assets": 13967000000,
"accounts_payable": 608000000,
"employee_compensation_and_benefits": 423000000,
"deferred_revenue": 640000000,
"short_term_debt": 304000000,
"other_accrued_liabilities": 314000000,
"total_current_liabilities": 2289000000,
"long_term_debt": 3645000000,
"retirement_and_post_retirement_benefits": 128000000,
"other_long_term_liabilities": 542000000,
"total_liabilities": 6604000000,
"total_stockholders_equity": 7363000000,
"total_debt": 3949000000,
"shares_outstanding": 281965813
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": 746000000,
"income_from_operations": 176000000
},
"agilent_crosslab": {
"net_revenue": 786000000,
"income_from_operations": 270000000
},
"applied_markets": {
"net_revenue": 346000000,
"income_from_operations": 86000000
},
"total_reportable_segment_income_from_operations": 532000000
},
"per_share": {
"dividends_declared_per_share": 0.255
}
},
{
"fiscal_year": 2025,
"fiscal_quarter": 3,
"label": "Q3 FY2025",
"period_start": "2025-05-01",
"period_end": "2025-07-31",
"period_type": "three months",
"source_accession": "0001090872-26-000064",
"income_statement": {
"product_revenue": 1230000000,
"services_and_other_revenue": 508000000,
"total_net_revenue": 1738000000,
"cost_of_products": 577000000,
"cost_of_services_and_other": 273000000,
"total_cost_of_revenue": 850000000,
"research_and_development": 111000000,
"selling_general_and_administrative": 417000000,
"total_costs_and_expenses": 1378000000,
"operating_income": 360000000,
"interest_income": 16000000,
"interest_expense": -28000000,
"other_income_expense_net": 18000000,
"income_before_taxes": 366000000,
"provision_for_income_taxes": 30000000,
"net_income": 336000000,
"basic_eps": 1.18,
"diluted_eps": 1.18,
"basic_shares": 284000000,
"diluted_shares": 285000000,
"gross_profit": 888000000
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": 670000000,
"income_from_operations": 118000000
},
"agilent_crosslab": {
"net_revenue": 744000000,
"income_from_operations": 248000000
},
"applied_markets": {
"net_revenue": 324000000,
"income_from_operations": 71000000
},
"total_reportable_segment_income_from_operations": 437000000
},
"per_share": {
"dividends_declared_per_share": 0.248
}
}
],
"year_to_date": {
"label": "Nine months ended July 31, 2026 (first nine months of FY2026)",
"period_start": "2025-11-01",
"period_end": "2026-07-31",
"period_type": "nine months",
"source_accession": "0001090872-26-000064",
"prior_year_comparative": {
"label": "Nine months ended July 31, 2025 (first nine months of FY2025)",
"period_start": "2024-11-01",
"period_end": "2025-07-31",
"period_type": "nine months",
"source_accession": "0001090872-26-000064",
"income_statement": {
"product_revenue": 3616000000,
"services_and_other_revenue": 1471000000,
"total_net_revenue": 5087000000,
"cost_of_products": 1650000000,
"cost_of_services_and_other": 784000000,
"total_cost_of_revenue": 2434000000,
"research_and_development": 336000000,
"selling_general_and_administrative": 1281000000,
"total_costs_and_expenses": 4051000000,
"operating_income": 1036000000,
"interest_income": 45000000,
"interest_expense": -85000000,
"other_income_expense_net": -3000000,
"income_before_taxes": 993000000,
"provision_for_income_taxes": 124000000,
"net_income": 869000000,
"basic_eps": 3.05,
"diluted_eps": 3.05,
"basic_shares": 285000000,
"diluted_shares": 285000000,
"gross_profit": 2653000000
},
"cash_flow": {
"depreciation_and_amortization": 217000000,
"share_based_compensation": 102000000,
"operating_cash_flow": 1014000000,
"capital_expenditures": -314000000,
"acquisitions_net_of_cash_acquired": 4000000,
"investing_cash_flow": -304000000,
"repurchase_of_common_stock": -340000000,
"dividends_paid": -212000000,
"proceeds_from_issuance_of_long_term_debt": 4000000,
"repayment_of_long_term_debt": -2000000,
"financing_cash_flow": -515000000,
"free_cash_flow": 700000000
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": 1971000000,
"income_from_operations": 364000000
},
"agilent_crosslab": {
"net_revenue": 2153000000,
"income_from_operations": 700000000
},
"applied_markets": {
"net_revenue": 963000000,
"income_from_operations": 214000000
},
"total_reportable_segment_income_from_operations": 1278000000
},
"per_share": {
"dividends_declared_per_share": 0.744
}
},
"income_statement": {
"product_revenue": 3911000000,
"services_and_other_revenue": 1600000000,
"total_net_revenue": 5511000000,
"cost_of_products": 1697000000,
"cost_of_services_and_other": 836000000,
"total_cost_of_revenue": 2533000000,
"research_and_development": 366000000,
"selling_general_and_administrative": 1416000000,
"total_costs_and_expenses": 4315000000,
"operating_income": 1196000000,
"interest_income": 43000000,
"interest_expense": -79000000,
"other_income_expense_net": 56000000,
"income_before_taxes": 1216000000,
"provision_for_income_taxes": 210000000,
"net_income": 1006000000,
"basic_eps": 3.55,
"diluted_eps": 3.55,
"basic_shares": 283000000,
"diluted_shares": 283000000,
"gross_profit": 2978000000
},
"cash_flow": {
"depreciation_and_amortization": 200000000,
"share_based_compensation": 105000000,
"operating_cash_flow": 1064000000,
"capital_expenditures": -249000000,
"acquisitions_net_of_cash_acquired": -950000000,
"investing_cash_flow": -1202000000,
"repurchase_of_common_stock": -295000000,
"dividends_paid": -216000000,
"proceeds_from_issuance_of_long_term_debt": 600000000,
"repayment_of_long_term_debt": -4000000,
"financing_cash_flow": 105000000,
"free_cash_flow": 815000000
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": 2157000000,
"income_from_operations": 446000000
},
"agilent_crosslab": {
"net_revenue": 2303000000,
"income_from_operations": 752000000
},
"applied_markets": {
"net_revenue": 1051000000,
"income_from_operations": 259000000
},
"total_reportable_segment_income_from_operations": 1457000000
},
"per_share": {
"dividends_declared_per_share": 0.765
}
},
"trailing_twelve_months": {
"label": "Twelve months ended July 31, 2026",
"period_start": "2025-08-01",
"period_end": "2026-07-31",
"period_type": "trailing twelve months",
"source_accession": "0001090872-26-000064",
"derived_from_accessions": [
"0001090872-25-000087",
"0001090872-26-000064"
],
"derivation": "FY2025 (Form 10-K, accession 0001090872-25-000087) plus the nine months ended July 31, 2026 less the nine months ended July 31, 2025 (Form 10-Q, accession 0001090872-26-000064)",
"income_statement": {
"gross_profit": 3968000000,
"product_revenue": 5239000000,
"services_and_other_revenue": 2133000000,
"total_net_revenue": 7372000000,
"total_cost_of_revenue": 3404000000,
"operating_income": 1639000000,
"income_before_taxes": 1658000000,
"provision_for_income_taxes": 218000000,
"net_income": 1440000000
},
"cash_flow": {
"free_cash_flow": 1267000000,
"depreciation_and_amortization": 271000000,
"operating_cash_flow": 1609000000,
"capital_expenditures": -342000000
}
},
"notes": [
"Agilent's fiscal year ends October 31 and its fiscal quarters end January 31, April 30 and July 31. FY2025 is the year ended October 31, 2025; Q3 FY2026 is the three months ended July 31, 2026.",
"Annual figures (FY2025, FY2024 and FY2023) are from the FY2025 Form 10-K (accession 0001090872-25-000087). That report prints three years of income statement and cash flow but only two balance sheets, so FY2023 carries no balance sheet.",
"Quarterly, nine-month and July 31, 2026 balance sheet figures are from the Q3 FY2026 Form 10-Q (accession 0001090872-26-000064). The 10-Q's October 31, 2025 balance sheet column matches the 10-K's FY2025 balance sheet line for line.",
"Template: standard industrial. Agilent sells laboratory instruments, consumables, software and services; revenue is reported as products plus services and other, and the statements present costs of products and of services but no gross profit line.",
"Gross profit is derived as total net revenue less total costs (cost of products plus cost of services and other), as the statements print no gross profit line. Free cash flow is derived as net cash provided by operating activities less payments to acquire property, plant and equipment; Agilent's statements do not present a free cash flow figure. Total debt is short-term debt plus long-term debt as printed on the balance sheet.",
"Weighted-average share counts are printed in millions, rounded to the nearest million, so they are stated here to that precision. Shares outstanding are the exact counts printed in the balance sheet's common stock caption.",
"Dividends declared per share are taken from the statements of equity: $0.992 (FY2025), $0.944 (FY2024), $0.900 (FY2023), $0.255 (Q3 FY2026), $0.248 (Q3 FY2025), $0.765 (nine months of FY2026) and $0.744 (nine months of FY2025).",
"The 10-Q prints its cash flow statement for the nine months only, so cash flow figures appear in the nine-month and trailing-twelve-month views rather than on the quarterly entries.",
"The trailing twelve months ended July 31, 2026 are derived as FY2025 plus the nine months ended July 31, 2026 less the nine months ended July 31, 2025. Per-share amounts are not derived for this view.",
"Segment figures are each reportable segment's net revenue and income from operations as reported in the segment note. Segment income from operations excludes restructuring, intangible amortization, transformational initiatives, acquisition and integration costs and other unallocated items, so the three segments sum to more than consolidated GAAP income from operations (for Q3 FY2026, $532 million of segment income against $444 million GAAP). Segment revenue sums to consolidated net revenue in every period.",
"Segment structure: in November 2024 Agilent reorganized into Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets, and the FY2025 10-K recast FY2024 and FY2023 segment results to that structure.",
"On June 24, 2026 Agilent acquired BC Midco I, Inc. (Biocare) for net consideration of $950 million, which accounts for the nine-month cash outflow for acquisitions and most of the increase in goodwill and other intangible assets since October 31, 2025. Biocare's results are included in the Life Sciences and Diagnostics Markets segment from the acquisition date.",
"No stock split occurred in the periods presented and Agilent is not an ADR issuer, so per-share figures are as filed, per share of common stock."
],
"uncertainties": [
"No discrete three-month cash flow figures are available for Q3 FY2026 or Q3 FY2025: the Q3 FY2026 10-Q and its accompanying earnings release (accession 0001090872-26-000062) print the cash flow statement for the nine months only. Quarterly operating cash flow, capital expenditures and free cash flow are therefore not reported here.",
"The FY2023 balance sheet is not presented in the FY2025 10-K, so no FY2023 balance sheet figures are reported."
],
"headline": {
"period": "Q3 FY2026",
"period_end_words": "July 31, 2026",
"metrics": [
{
"label": "Revenue",
"format": "usd",
"value": 1878000000,
"text": "$1.88 billion",
"exact": "$1,878,000,000",
"compact": "$1.88B",
"abs": "$1.88 billion",
"prior_value": 1738000000,
"prior": "$1.74 billion",
"priorabs": "$1.74 billion",
"yoy": "up 8.1%",
"source": {
"array": "quarterly",
"field": "income_statement.total_net_revenue",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-07-31",
"period_start": "2026-05-01",
"span_days": 91,
"source_accession": "0001090872-26-000064",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-07-31",
"prior_period_start": "2025-05-01",
"prior_span_days": 91,
"prior_source_accession": "0001090872-26-000064",
"gap_days": 365
}
},
{
"label": "Net income",
"format": "usd",
"value": 362000000,
"text": "$362 million",
"exact": "$362,000,000",
"compact": "$362.00M",
"abs": "$362 million",
"prior_value": 336000000,
"prior": "$336 million",
"priorabs": "$336 million",
"yoy": "up 7.7%",
"source": {
"array": "quarterly",
"field": "income_statement.net_income",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-07-31",
"period_start": "2026-05-01",
"span_days": 91,
"source_accession": "0001090872-26-000064",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-07-31",
"prior_period_start": "2025-05-01",
"prior_span_days": 91,
"prior_source_accession": "0001090872-26-000064",
"gap_days": 365
}
},
{
"label": "Diluted EPS",
"format": "eps",
"value": 1.28,
"text": "$1.28",
"exact": "$1.28",
"compact": "$1.28",
"abs": "$1.28",
"prior_value": 1.18,
"prior": "$1.18",
"priorabs": "$1.18",
"yoy": "up 8.5%",
"source": {
"array": "quarterly",
"field": "income_statement.diluted_eps",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-07-31",
"period_start": "2026-05-01",
"span_days": 91,
"source_accession": "0001090872-26-000064",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-07-31",
"prior_period_start": "2025-05-01",
"prior_span_days": 91,
"prior_source_accession": "0001090872-26-000064",
"gap_days": 365
}
},
{
"label": "Operating income",
"format": "usd",
"value": 444000000,
"text": "$444 million",
"exact": "$444,000,000",
"compact": "$444.00M",
"abs": "$444 million",
"prior_value": 360000000,
"prior": "$360 million",
"priorabs": "$360 million",
"yoy": "up 23.3%",
"source": {
"array": "quarterly",
"field": "income_statement.operating_income",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-07-31",
"period_start": "2026-05-01",
"span_days": 91,
"source_accession": "0001090872-26-000064",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-07-31",
"prior_period_start": "2025-05-01",
"prior_span_days": 91,
"prior_source_accession": "0001090872-26-000064",
"gap_days": 365
}
}
],
"summary": "Agilent Technologies reported $1.88 billion in revenue for Q3 FY2026, the quarter ended July 31, 2026, up 8.1% from a year earlier, with growth in all three of its segments. Income from operations was $444 million, up 23.3%, helped by higher volume, targeted price increases, favorable mix and refunds of tariffs it had previously paid. Net income was $362 million, or $1.28 per diluted share, against $336 million, or $1.18, a smaller gain because Agilent's effective tax rate rose, partly because a tax reserve release had lowered it in the year-ago quarter.",
"qa": [
{
"q": "How much revenue did Agilent report in Q3 FY2026?",
"a": "Agilent Technologies reported $1.88 billion in revenue for Q3 FY2026, the quarter ended July 31, 2026. That is up 8.1% from $1.74 billion in the same quarter a year earlier, with all three of its segments growing."
},
{
"q": "What was Agilent's net income in Q3 FY2026?",
"a": "Agilent Technologies earned net income of $362 million in Q3 FY2026, the quarter ended July 31, 2026, up 7.7% from $336 million a year earlier. Net income grew more slowly than income from operations because Agilent's effective tax rate rose, partly because a tax reserve release had lowered it in the year-ago quarter."
},
{
"q": "What was Agilent's earnings per share in Q3 FY2026?",
"a": "Agilent Technologies reported diluted earnings per share of $1.28 for Q3 FY2026, the quarter ended July 31, 2026, up 8.5% from $1.18 in the same quarter a year earlier."
},
{
"q": "Why did Agilent's operating income rise in Q3 FY2026?",
"a": "Agilent Technologies' income from operations was $444 million in Q3 FY2026, up 23.3% from $360 million a year earlier. The company attributed its higher operating margin to higher sales volume, a net benefit from refunds of tariffs it had previously paid and lower restructuring costs, partly offset by higher wages, variable pay and higher costs from transformational initiatives."
}
]
},
"company_details": {
"Name": "Agilent Technologies, Inc.",
"Ticker": "A",
"CIK": "0001090872",
"Exchange": "NYSE",
"State": "California",
"Incorporation": "Delaware",
"SIC": "3826",
"Office": "Industrial Applications and Services",
"Industry": "Laboratory Analytical Instruments"
},
"next_filing": {
"predicted_date": "2026-12-21",
"predicted_type": "10-K"
},
"fiscal_period": {
"fiscal_year": 2026,
"fiscal_period": "Q3",
"tag": "FY26Q3",
"period_end": "2026-07-31",
"form": "10-Q",
"accession": "0001090872-26-000064",
"fiscal_year_end": "1031",
"source": "facts"
},
"source_filings": [
{
"role": "annual",
"current": false,
"form": "10-K",
"fiscal_year": 2025,
"fiscal_period": "FY",
"tag": "FY25",
"period_end": "2025-10-31",
"filed": "2025-12-22",
"accession": "0001090872-25-000087",
"url": "https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm",
"source": "reported"
},
{
"role": "quarterly",
"current": true,
"form": "10-Q",
"fiscal_year": 2026,
"fiscal_period": "Q3",
"tag": "FY26Q3",
"period_end": "2026-07-31",
"filed": "2026-09-01",
"accession": "0001090872-26-000064",
"url": "https://www.sec.gov/Archives/edgar/data/1090872/000109087226000064/a-20260731.htm",
"source": "facts"
}
],
"figure_sources": {
"about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '<document>#<anchor>', and the link is documents[<document>] + '#<anchor>': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release.",
"documents": {
"d1": "https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm",
"d2": "https://www.sec.gov/Archives/edgar/data/1090872/000109087226000064/a-20260731.htm"
},
"annual": [
{
"period_end": "2025-10-31",
"income_statement": {
"product_revenue": "d1#f-56",
"services_and_other_revenue": "d1#f-59",
"total_net_revenue": "d1#f-62",
"cost_of_products": "d1#f-65",
"cost_of_services_and_other": "d1#f-68",
"total_cost_of_revenue": "d1#f-71",
"research_and_development": "d1#f-74",
"selling_general_and_administrative": "d1#f-77",
"total_costs_and_expenses": "d1#f-80",
"operating_income": "d1#f-83",
"interest_income": "d1#f-86",
"interest_expense": "d1#f-89",
"other_income_expense_net": "d1#f-92",
"income_before_taxes": "d1#f-95",
"provision_for_income_taxes": "d1#f-98",
"net_income": "d1#f-101",
"basic_eps": "d1#f-104",
"diluted_eps": "d1#f-107",
"basic_shares": "d1#f-110",
"diluted_shares": "d1#f-113"
},
"balance_sheet": {
"cash_and_cash_equivalents": "d1#f-155",
"accounts_receivable_net": "d1#f-157",
"inventory": "d1#f-159",
"other_current_assets": "d1#f-161",
"total_current_assets": "d1#f-163",
"property_plant_and_equipment_net": "d1#f-165",
"goodwill": "d1#f-167",
"other_intangible_assets_net": "d1#f-169",
"long_term_investments": "d1#f-171",
"other_assets": "d1#f-173",
"total_assets": "d1#f-175",
"accounts_payable": "d1#f-177",
"employee_compensation_and_benefits": "d1#f-179",
"deferred_revenue": "d1#f-181",
"short_term_debt": "d1#f-183",
"other_accrued_liabilities": "d1#f-185",
"total_current_liabilities": "d1#f-187",
"long_term_debt": "d1#f-189",
"retirement_and_post_retirement_benefits": "d1#f-191",
"other_long_term_liabilities": "d1#f-193",
"total_liabilities": "d1#f-195",
"total_stockholders_equity": "d1#f-225",
"shares_outstanding": "d1#f-213"
},
"cash_flow": {
"depreciation_and_amortization": "d1#f-232",
"share_based_compensation": "d1#f-235",
"operating_cash_flow": "d1#f-274",
"capital_expenditures": "d1#f-277",
"acquisitions_net_of_cash_acquired": "d1#f-295",
"investing_cash_flow": "d1#f-298",
"repurchase_of_common_stock": "d1#f-307",
"dividends_paid": "d1#f-313",
"proceeds_from_issuance_of_long_term_debt": "d1#f-316",
"repayment_of_long_term_debt": "d1#f-319",
"financing_cash_flow": "d1#f-331"
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": "d1#f-560",
"income_from_operations": "d1#f-2407"
},
"agilent_crosslab": {
"net_revenue": "d1#f-561",
"income_from_operations": "d1#f-2408"
},
"applied_markets": {
"net_revenue": "d1#f-562",
"income_from_operations": "d1#f-840"
},
"total_reportable_segment_income_from_operations": "d1#f-2410"
},
"per_share": {
"dividends_declared_per_share": "d1#f-419"
}
},
{
"period_end": "2024-10-31",
"income_statement": {
"product_revenue": "d1#f-57",
"services_and_other_revenue": "d1#f-60",
"total_net_revenue": "d1#f-63",
"cost_of_products": "d1#f-66",
"cost_of_services_and_other": "d1#f-69",
"total_cost_of_revenue": "d1#f-72",
"research_and_development": "d1#f-75",
"selling_general_and_administrative": "d1#f-78",
"total_costs_and_expenses": "d1#f-81",
"operating_income": "d1#f-84",
"interest_income": "d1#f-87",
"interest_expense": "d1#f-90",
"other_income_expense_net": "d1#f-93",
"income_before_taxes": "d1#f-96",
"provision_for_income_taxes": "d1#f-99",
"net_income": "d1#f-102",
"basic_eps": "d1#f-105",
"diluted_eps": "d1#f-108",
"basic_shares": "d1#f-111",
"diluted_shares": "d1#f-114"
},
"balance_sheet": {
"cash_and_cash_equivalents": "d1#f-156",
"accounts_receivable_net": "d1#f-158",
"inventory": "d1#f-160",
"other_current_assets": "d1#f-162",
"total_current_assets": "d1#f-164",
"property_plant_and_equipment_net": "d1#f-166",
"goodwill": "d1#f-168",
"other_intangible_assets_net": "d1#f-170",
"long_term_investments": "d1#f-172",
"other_assets": "d1#f-174",
"total_assets": "d1#f-176",
"accounts_payable": "d1#f-178",
"employee_compensation_and_benefits": "d1#f-180",
"deferred_revenue": "d1#f-182",
"short_term_debt": "d1#f-184",
"other_accrued_liabilities": "d1#f-186",
"total_current_liabilities": "d1#f-188",
"long_term_debt": "d1#f-190",
"retirement_and_post_retirement_benefits": "d1#f-192",
"other_long_term_liabilities": "d1#f-194",
"total_liabilities": "d1#f-196",
"total_stockholders_equity": "d1#f-226",
"shares_outstanding": "d1#f-215"
},
"cash_flow": {
"depreciation_and_amortization": "d1#f-233",
"share_based_compensation": "d1#f-236",
"operating_cash_flow": "d1#f-275",
"capital_expenditures": "d1#f-278",
"acquisitions_net_of_cash_acquired": "d1#f-296",
"investing_cash_flow": "d1#f-299",
"repurchase_of_common_stock": "d1#f-308",
"dividends_paid": "d1#f-314",
"proceeds_from_issuance_of_long_term_debt": "d1#f-317",
"repayment_of_long_term_debt": "d1#f-320",
"financing_cash_flow": "d1#f-332"
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": "d1#f-576",
"income_from_operations": "d1#f-2424"
},
"agilent_crosslab": {
"net_revenue": "d1#f-577",
"income_from_operations": "d1#f-2425"
},
"applied_markets": {
"net_revenue": "d1#f-578",
"income_from_operations": "d1#f-2426"
},
"total_reportable_segment_income_from_operations": "d1#f-2427"
},
"per_share": {
"dividends_declared_per_share": "d1#f-394"
}
},
{
"period_end": "2023-10-31",
"income_statement": {
"product_revenue": "d1#f-58",
"services_and_other_revenue": "d1#f-61",
"total_net_revenue": "d1#f-64",
"cost_of_products": "d1#f-67",
"cost_of_services_and_other": "d1#f-70",
"total_cost_of_revenue": "d1#f-73",
"research_and_development": "d1#f-76",
"selling_general_and_administrative": "d1#f-79",
"total_costs_and_expenses": "d1#f-82",
"operating_income": "d1#f-85",
"interest_income": "d1#f-88",
"interest_expense": "d1#f-91",
"other_income_expense_net": "d1#f-94",
"income_before_taxes": "d1#f-97",
"provision_for_income_taxes": "d1#f-100",
"net_income": "d1#f-103",
"basic_eps": "d1#f-106",
"diluted_eps": "d1#f-109",
"basic_shares": "d1#f-112",
"diluted_shares": "d1#f-115"
},
"cash_flow": {
"depreciation_and_amortization": "d1#f-234",
"share_based_compensation": "d1#f-237",
"operating_cash_flow": "d1#f-276",
"capital_expenditures": "d1#f-279",
"acquisitions_net_of_cash_acquired": "d1#f-297",
"investing_cash_flow": "d1#f-300",
"repurchase_of_common_stock": "d1#f-309",
"dividends_paid": "d1#f-315",
"financing_cash_flow": "d1#f-333"
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": "d1#f-592",
"income_from_operations": "d1#f-2441"
},
"agilent_crosslab": {
"net_revenue": "d1#f-593",
"income_from_operations": "d1#f-2442"
},
"applied_markets": {
"net_revenue": "d1#f-594",
"income_from_operations": "d1#f-2443"
},
"total_reportable_segment_income_from_operations": "d1#f-2444"
},
"per_share": {
"dividends_declared_per_share": "d1#f-369"
}
}
],
"quarterly": [
{
"period_end": "2026-07-31",
"income_statement": {
"product_revenue": "d2#f-30",
"services_and_other_revenue": "d2#f-34",
"total_net_revenue": "d2#f-38",
"cost_of_products": "d2#f-42",
"cost_of_services_and_other": "d2#f-46",
"total_cost_of_revenue": "d2#f-50",
"research_and_development": "d2#f-54",
"selling_general_and_administrative": "d2#f-58",
"total_costs_and_expenses": "d2#f-62",
"operating_income": "d2#f-66",
"interest_income": "d2#f-70",
"interest_expense": "d2#f-74",
"other_income_expense_net": "d2#f-78",
"income_before_taxes": "d2#f-82",
"provision_for_income_taxes": "d2#f-86",
"net_income": "d2#f-90",
"basic_eps": "d2#f-94",
"diluted_eps": "d2#f-98",
"basic_shares": "d2#f-102",
"diluted_shares": "d2#f-106"
},
"balance_sheet": {
"cash_and_cash_equivalents": "d2#f-162",
"accounts_receivable_net": "d2#f-164",
"inventory": "d2#f-166",
"other_current_assets": "d2#f-168",
"total_current_assets": "d2#f-170",
"property_plant_and_equipment_net": "d2#f-172",
"goodwill": "d2#f-174",
"other_intangible_assets_net": "d2#f-176",
"long_term_investments": "d2#f-178",
"other_assets": "d2#f-180",
"total_assets": "d2#f-182",
"accounts_payable": "d2#f-184",
"employee_compensation_and_benefits": "d2#f-186",
"deferred_revenue": "d2#f-188",
"short_term_debt": "d2#f-190",
"other_accrued_liabilities": "d2#f-192",
"total_current_liabilities": "d2#f-194",
"long_term_debt": "d2#f-196",
"retirement_and_post_retirement_benefits": "d2#f-198",
"other_long_term_liabilities": "d2#f-200",
"total_liabilities": "d2#f-202",
"total_stockholders_equity": "d2#f-232",
"shares_outstanding": "d2#f-220"
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": "d2#f-513",
"income_from_operations": "d2#f-1375"
},
"agilent_crosslab": {
"net_revenue": "d2#f-514",
"income_from_operations": "d2#f-1376"
},
"applied_markets": {
"net_revenue": "d2#f-515",
"income_from_operations": "d2#f-1377"
},
"total_reportable_segment_income_from_operations": "d2#f-1378"
},
"per_share": {
"dividends_declared_per_share": "d2#f-325"
}
},
{
"period_end": "2025-07-31",
"income_statement": {
"product_revenue": "d2#f-31",
"services_and_other_revenue": "d2#f-35",
"total_net_revenue": "d2#f-39",
"cost_of_products": "d2#f-43",
"cost_of_services_and_other": "d2#f-47",
"total_cost_of_revenue": "d2#f-51",
"research_and_development": "d2#f-55",
"selling_general_and_administrative": "d2#f-59",
"total_costs_and_expenses": "d2#f-63",
"operating_income": "d2#f-67",
"interest_income": "d2#f-71",
"interest_expense": "d2#f-75",
"other_income_expense_net": "d2#f-79",
"income_before_taxes": "d2#f-83",
"provision_for_income_taxes": "d2#f-87",
"net_income": "d2#f-91",
"basic_eps": "d2#f-95",
"diluted_eps": "d2#f-99",
"basic_shares": "d2#f-103",
"diluted_shares": "d2#f-107"
},
"segments": {
"life_sciences_and_diagnostics_markets": {
"net_revenue": "d2#f-517",
"income_from_operations": "d2#f-1392"
},
"agilent_crosslab": {
"net_revenue": "d2#f-518",
"income_from_operations": "d2#f-1393"
},
"applied_markets": {
"net_revenue": "d2#f-519",
"income_from_operations": "d2#f-1247"
},
"total_reportable_segment_income_from_operations": "d2#f-1395"
},
"per_share": {
"dividends_declared_per_share": "d2#f-385"
}
}
]
}
}